These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39475028)

  • 1. Ganglioglioma with
    Zhao C; Li C; Ge JJ; Zhang JP
    Br J Hosp Med (Lond); 2024 Oct; 85(10):1-10. PubMed ID: 39475028
    [No Abstract]   [Full Text] [Related]  

  • 2. An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion.
    Cheaney B; Bowden S; Krause K; Sloan EA; Perry A; Solomon DA; Han SJ; Wood MD
    Acta Neuropathol Commun; 2019 Jul; 7(1):110. PubMed ID: 31288852
    [No Abstract]   [Full Text] [Related]  

  • 3. The genetic landscape of ganglioglioma.
    Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
    Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathological characteristics of gangliogliomas with anaplastic morphology].
    Guo LA; Wang LM; Fu YJ; Luo T; Fan XT; Zhao LH; Yao XH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):585-591. PubMed ID: 38825904
    [No Abstract]   [Full Text] [Related]  

  • 7. Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    Vizcaino MA; Giannini C; Lalich D; Nael A; Jenkins RB; Tran Q; Orr BA; Abdullaev Z; Aldape K; Vaubel RA
    J Neuropathol Exp Neurol; 2024 May; 83(6):416-424. PubMed ID: 38699943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated genotype-phenotype analysis of long-term epilepsy-associated ganglioglioma.
    Wang Y; Wang L; Blümcke I; Zhang W; Fu Y; Shan Y; Piao Y; Zhao G
    Brain Pathol; 2022 Jan; 32(1):e13011. PubMed ID: 34355449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas.
    Frazão L; do Carmo Martins M; Nunes VM; Pimentel J; Faria C; Miguéns J; Sagarribay A; Matos M; Salgado D; Nunes S; Mafra M; Roque L
    BMC Cancer; 2018 Dec; 18(1):1259. PubMed ID: 30558563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma.
    Lucas CG; Davidson CJ; Alashari M; Putnam AR; Whipple NS; Bruggers CS; Mendez JS; Cheshier SH; Walker JB; Ramani B; Cadwell CR; Sullivan DV; Lu R; Mirchia K; Van Ziffle J; Devine P; Goldschmidt E; Hervey-Jumper SL; Gupta N; Oberheim Bush NA; Raleigh DR; Bollen A; Tihan T; Pekmezci M; Solomon DA; Phillips JJ; Perry A
    J Neuropathol Exp Neurol; 2022 Jul; 81(8):650-657. PubMed ID: 35703914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.
    Xerri L; Adélaïde J; Popovici C; Garnier S; Guille A; Mescam-Mancini L; Laurent C; Brousset P; Coze C; Michel G; Chaffanet M; Bouabdallah R; Coso D; Bertucci F; Birnbaum D
    Am J Surg Pathol; 2018 Feb; 42(2):150-159. PubMed ID: 29194093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation.
    Chatterjee D; Garg C; Singla N; Radotra BD
    Hum Pathol; 2018 Oct; 80():186-191. PubMed ID: 29902580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
    Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours.
    Dyke J; Calapre L; Beasley A; Gray E; Allcock R; Bentel J
    Pathol Res Pract; 2022 Jan; 229():153724. PubMed ID: 34942511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of ganglioglioma grade 3 with H3 K27M mutation arising in the medial temporal lobe in an elderly patient.
    Fujii Y; Hatae R; Hata N; Suzuki SO; Sangatsuda Y; Takigawa K; Funakoshi Y; Fujioka Y; Kuga D; Mizoguchi M; Iwaki T; Yoshimoto K
    Neuropathology; 2022 Jun; 42(3):197-203. PubMed ID: 35187715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastomatous transformation of ganglioglioma: case report with reference to molecular genetic and flow cytometric analysis.
    Kim NR; Wang KC; Bang JS; Choe G; Park Y; Kim SK; Cho BK; Chi JG
    Pathol Int; 2003 Dec; 53(12):874-82. PubMed ID: 14629754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atypical ganglioglioma with BRAF V600E mutation: a case report and review of the literature].
    Martinez-Ricarte F; Martinez-Saez E; Cicuendez M; Cordero E; Auger C; Toledo M; Radoi A; Sahuquillo J
    Rev Neurol; 2016 May; 62(10):455-9. PubMed ID: 27149188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.